Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Weleader Biomedical Co's Total Assets for the quarter that ended in Dec. 2025 was NT$2,449 Mil.
Warning Sign:
If a company builds assets at 24.6% a year, faster than its revenue growth rate of 2.9% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Weleader Biomedical Co's average Total Assets Growth Rate was 18.40% per year.
During the past 3 years, the average Total Assets Growth Rate was 12.40% per year.
During the past 5 years, the average Total Assets Growth Rate was 24.60% per year.
During the past 6 years, Weleader Biomedical Co's highest 3-Year average Total Assets Growth Rate was 32.70%. The lowest was 12.40%. And the median was 28.30%.
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Weleader Biomedical Co's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Weleader Biomedical Co Total Assets Related Terms
Weleader Biomedical Co Total Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Weleader Biomedical Co's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Weleader Biomedical Co (ROCO:7713) has a Total Assets of NT$2,449 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Weleader Biomedical Co and its competitors.
Is Weleader Biomedical Co's Total Assets too high?
Weleader Biomedical Co's current Total Assets is NT$2,449 Mil. Overall, Weleader Biomedical Co has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Weleader Biomedical Co's Total Assets compare to ABT and SYK?
Weleader Biomedical Co's Total Assets of NT$2,449 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Medical Devices & Instruments company?
A good Total Assets depends on the Medical Devices & Instruments industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Weleader Biomedical Co and its competitors. Weleader Biomedical Co's current Total Assets is NT$2,449 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weleader Biomedical Co stock overvalued right now?
Weleader Biomedical Co (ROCO:7713) has a current Total Assets of NT$2,449 Mil. The current Total Assets is NT$2,449 Mil. Weleader Biomedical Co's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Weleader Biomedical Co (ROCO:7713), the current Total Assets is NT$2,449 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
47GF Score
Get the complete analysis for ROCO:7713
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7713 has been successfully added to your 
